Animal-derived medicinal products in Russia: Current nomenclature and specific aspects of quality control

Prokopov, Ilya A.; Ковалева, Е. Л.; Minaeva, Elena D.; Pryakhina, Ekaterina A.; Savin, Evgenyi V.; Gamayunova, Alexandra V.; Pozharitskaya, Olga N.; Makarov, Valery G.; Shikov, Alexander N.

doi:10.1016/j.jep.2019.111933

Cited by 31 publications

(14 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The composition of animal-derived medicinal products is very complicated [30]. Just a few peptides have been reported from sea urchins, and limited information is available about its structure [8,13,14,16,18].…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic Study of Bioactive Glycopeptide from Strongylocentrotus droebachiensis After Intranasal Administration to Rats Using Biomarker Approach

Shikov

Pozharitskaya²,

Фаустова³

et al. 2019

Marine Drugs

View full text Add to dashboard Cite

A glycopeptide fraction (GPF) from internal organs of green sea urchins (Strongylocentrotus droebachiensis Müller, Strongylocentrotidae) has been reported to be an effective bronchitis treatment. In this study, we evaluated the pharmacokinetic and tissue distribution of GPF, following single and repeated intranasal (i/n) administration over the course of seven days in rats. The method measuring lactate dehydrogenase as biomarker was used to analyse the plasma and tissue concentrations of GPF. GPF appears in the plasma 15 min after single i/n administration (100 µg/kg) and reaches its maximum at 45 min. The area under the curve (AUC)0–24 and Cmax were similar using both i/n and intravenous administration, while mean residence time (MRT) and T1/2 after i/n administration were significantly higher compared with intravenous (i/v) administration. The absolute bioavailability of GPF after i/n administration was 89%. The values of tissue availability (ft) provided evidence about the highest concentration of GPF in the nose mucosa (ft = 34.9), followed by spleen (ft = 4.1), adrenal glands (ft = 3.8), striated muscle (ft = 1.8), kidneys (ft = 0.5), and liver (ft = 0.3). After repeated dose administration, GPF exhibited significantly higher AUC0–24 and MRT, indicating its accumulation in the plasma.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic Study of Bioactive Glycopeptide from Strongylocentrotus droebachiensis After Intranasal Administration to Rats Using Biomarker Approach

Shikov

Pozharitskaya²,

Фаустова³

et al. 2019

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…Phytotherapy and zootherapy are a part of officinal medicine in Russia [ 96 - 98 ]. The Federal Law No.…”

Section: Regulationsmentioning

confidence: 99%

Sceletium for Managing Anxiety, Depression and Cognitive Impairment: A Traditional Herbal Medicine in Modern-Day Regulatory Systems

Brendler

Brinckmann²,

Feiter³

et al. 2021

Self Cite

View full text Add to dashboard Cite

: Modern-day regulatory systems governing conditions for how health products enter national markets constitute a barrier of access for traditional herbal medicines on an international level. Regulatory intentions are focused on ensuring consumers are being provided with safe, efficacious and high-quality products that, however, collaterally limit opportunities for traditional herbal medicinal products, especially those that do not already have a long-standing tradition of use established in the respective national marketplaces. This case study investigates and compares how a Southern African herbal medicine with great potential as an anxiolytic and mild antidepressant – Mesembryanthemum tortuosum L. [syn. Sceletium tortuosum (L.) N.E.Br.] aerial parts – fares internationally in today’s regulatory environments. It is argued that inadvertent regulatory favoritism combined with the lack of means for adequate protection of intellectual property may obstruct innovation by creating an almost insurmountable economical hurdle for successful product development and introduction of botanicals from developing countries into most of the world’s health product markets.

show abstract

“…Echinochrome A (Ech A) is a marine-derived polyhydroxynaphthoquinone (Figure 1A) approved for medical use in Russia (PubChem CID: 135457951, C 12 H 10 O 7 ) [14][15][16][17][18]. Ech A is known for its anti-inflammatory, antimicrobial, and antioxidative effects [19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Echinochrome A Treatment Alleviates Atopic Dermatitis-like Skin Lesions in NC/Nga Mice via IL-4 and IL-13 Suppression

et al. 2021

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory skin disease in which skin barrier dysfunction leads to dryness, pruritus, and erythematous lesions. AD is triggered by immune imbalance and oxidative stress. Echinochrome A (Ech A), a natural pigment isolated from sea urchins, exerts antioxidant and beneficial effects in various inflammatory disease models. In the present study, we tested whether Ech A treatment alleviated AD-like skin lesions. We examined the anti-inflammatory effect of Ech A on 2,4-dinitrochlorobenzene (DNCB)-induced AD-like lesions in an NC/Nga mouse model. AD-like skin symptoms were induced by treatment with 1% DNCB for 1 week and 0.4% DNCB for 5 weeks in NC/Nga mice. The results showed that Ech A alleviated AD clinical symptoms, such as edema, erythema, and dryness. Treatment with Ech A induced the recovery of epidermis skin lesions as observed histologically. Tewameter® and Corneometer® measurements indicated that Ech A treatment reduced transepidermal water loss and improved stratum corneum hydration, respectively. Ech A treatment also inhibited inflammatory-response-induced mast cell infiltration in AD-like skin lesions and suppressed the expression of proinflammatory cytokines, such as interferon-γ, interleukin-4, and interleukin-13. Collectively, these results suggest that Ech A may be beneficial for treating AD owing to its anti-inflammatory effects.

show abstract

Animal-derived medicinal products in Russia: Current nomenclature and specific aspects of quality control

Cited by 31 publications

References 109 publications

Pharmacokinetic Study of Bioactive Glycopeptide from Strongylocentrotus droebachiensis After Intranasal Administration to Rats Using Biomarker Approach

Pharmacokinetic Study of Bioactive Glycopeptide from Strongylocentrotus droebachiensis After Intranasal Administration to Rats Using Biomarker Approach

Sceletium for Managing Anxiety, Depression and Cognitive Impairment: A Traditional Herbal Medicine in Modern-Day Regulatory Systems

Echinochrome A Treatment Alleviates Atopic Dermatitis-like Skin Lesions in NC/Nga Mice via IL-4 and IL-13 Suppression

Contact Info

Product

Resources

About